Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue

Chemokine receptor modeling: an interdisciplinary approach to drug design

(2013) Simon P Fricker et al.   Future Medicinal Chemistry

Design of Substituted Imidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication

(2013) Renato Skerlj et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex

(2013) Q. Tan et al.   SCIENCE

Is the CCR5 Δ 32 Mutation Associated with Immune System-Related Diseases?

(2012) Khodayar Ghorban et al.   INFLAMMATION

Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico Study

(2012) Gugan Kothandan et al.   PLoS One

Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)

(2011) Javier Garcia-Perez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Allosteric and Orthosteric Sites in CC Chemokine Receptor (CCR5), a Chimeric Receptor Approach

(2011) Stefanie Thiele et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prospective CCR5 Small Molecule Antagonist Compound Design Using a Combined Mutagenesis/Modeling Approach

(2011) Markus Metz et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

HIV-1 entry inhibition by small-molecule CCR5 antagonists: A combined molecular modeling and mutant study using a high-throughput assay

(2011) Jean Labrecque et al.   VIROLOGY

Chemokine receptor CCR5: from AIDS to atherosclerosis

(2010) KL Jones et al.   BRITISH JOURNAL OF PHARMACOLOGY

Maraviroc

(2010) Caroline M. Perry   DRUGS

Treatment of HIV infection with the CCR5 antagonist maraviroc

(2010) Wiete Kromdijk et al.   EXPERT OPINION ON PHARMACOTHERAPY

Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication

(2010) Renato T. Skerlj et al.   JOURNAL OF MEDICINAL CHEMISTRY

The chemokine receptor CCR5 in the central nervous system

(2010) Silvia Sorce et al.   PROGRESS IN NEUROBIOLOGY

Entry inhibitors in the treatment of HIV-1 infection

(2009) John C. Tilton et al.   ANTIVIRAL RESEARCH

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

(2009) J. F. DiPersio et al.   BLOOD

Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4‐Tropic HIV Type 1

(2009) Graeme Moyle et al.   CLINICAL INFECTIOUS DISEASES

Maraviroc: a new CCR5 antagonist

(2009) Shilpa Sayana et al.   Expert Review of Anti-Infective Therapy

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

(2009) John F. DiPersio et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors

(2008) R. S. Y. Wong et al.   MOLECULAR PHARMACOLOGY

Chemokines and Their Receptors: Drug Targets in Immunity and Inflammation

(2007) Antonella Viola et al.   Annual Review of Pharmacology and Toxicology